Clinical Trials Logo

Metastasis to Liver clinical trials

View clinical trials related to Metastasis to Liver.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06317181 Not yet recruiting - Liver Diseases Clinical Trials

Assessment of Liver Diseases Using a Deep-Learning Approach Based on Ultrasound RF-Data

LivSPECTRUS
Start date: April 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to test the performance of neuronal networks trained on ultrasonic raw Data (=radiofrequency data) for the assessment of liver diseases in patients undergoing a clinical ultrasound examination. The general feasibility is currently evaluated in a retrospective cohort. The main questions the study aims to answer are: - Can a neuronal network trained on RF Data perform equally good as elastography in the assessment of diffuse liver diseases? - Can a neuronal network trained on RF Data perform better than a neuronal network trained on b-mode images in the assessment of diffuse liver diseases? - Can a neuronal network trained on RF Data distinguish focal pathologies in the liver from healthy tissue? To answer these questions participants with a clinically indicated fibroscan will undergo: - a clinical elastography in Case ob suspected diffuse liver disease - a reliable ground truth (if normal ultrasound is not sufficient e.g. contrast enhanced ultrasound, biopsy, MRI or CT) in case of focal liver diseases, depending on the standard routine of the participating center - a clinical ultrasound examination during which b-mode images and the corresponding RF-Data sets are captured

NCT ID: NCT05681949 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Therapeutic Assistance and Decision-making Algorithms in Hepatobiliary Tumor Boards

ADBoard
Start date: November 2023
Phase: N/A
Study type: Interventional

The goal of this observational study is to compare the recommendations of the artificial intelligence clinical decision support system 'ADBoard', with the recommendations of physicians by tumor conferences in patients with hepatobiliary tumors. The main questions it aims to answer are: Can ADBoard achieve a high level of similar recommendations as physicians' tumor conferences? Can ADBoard consider a more complete set of patient-related data than in physicians' tumor conferences? Can ADBoard reduce the time between the first time the patient is discussed at the tumor conference and the start of the recommended treatment plan? Participants will have their hepatobiliary tumor treatments determined by either tumor conference with ADBoard, or tumor conference without ADBoard.